T
48.92
-2.45 (-4.77%)
| Penutupan Terdahulu | 51.37 |
| Buka | 51.33 |
| Jumlah Dagangan | 688,400 |
| Purata Dagangan (3B) | 670,700 |
| Modal Pasaran | 2,014,828,800 |
| Harga / Jualan (P/S) | 10.63 |
| Harga / Buku (P/B) | 9.49 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
| Margin Keuntungan | -63.16% |
| Margin Operasi (TTM) | -36.77% |
| EPS Cair (TTM) | -3.07 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 407.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 32.27% |
| Nisbah Semasa (MRQ) | 4.43 |
| Aliran Tunai Operasi (OCF TTM) | -83.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -50.48 M |
| Pulangan Atas Aset (ROA TTM) | -23.46% |
| Pulangan Atas Ekuiti (ROE TTM) | -54.83% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Tarsus Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.3
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -5.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.30 |
|
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 8.28% |
| % Dimiliki oleh Institusi | 103.10% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 78.00 (Guggenheim, 59.44%) | Beli |
| Median | 72.00 (47.18%) | |
| Rendah | 58.00 (Jefferies, 18.56%) | Beli |
| Purata | 68.20 (39.41%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 43.87 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jefferies | 06 Mar 2025 | 58.00 (18.56%) | Beli | 43.57 |
| Barclays | 26 Feb 2025 | 60.00 (22.65%) | Beli | 42.56 |
| 27 Jan 2025 | 62.00 (26.74%) | Beli | 51.45 | |
| Guggenheim | 26 Feb 2025 | 78.00 (59.44%) | Beli | 42.56 |
| HC Wainwright & Co. | 26 Feb 2025 | 73.00 (49.22%) | Beli | 42.56 |
| Oppenheimer | 22 Jan 2025 | 72.00 (47.18%) | Beli | 48.11 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| AZAMIAN BOBAK R. | - | 52.36 | -6,000 | -314,160 |
| Jumlah Keseluruhan Kuantiti Bersih | -6,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -314,160 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 52.36 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| AZAMIAN BOBAK R. | Pegawai | 24 Mar 2025 | Jual automatik (-) | 6,000 | 52.36 | 314,160 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Mar 2025 | Pengumuman | Tarsus Announces Proposed $100.0 Million Public Offering |
| 06 Mar 2025 | Pengumuman | Tarsus to Participate in Upcoming Investor Conference |
| 25 Feb 2025 | Pengumuman | Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements |
| 20 Feb 2025 | Pengumuman | Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 |
| 30 Jan 2025 | Pengumuman | Tarsus to Participate in Upcoming Investor Conferences |
| 13 Jan 2025 | Pengumuman | Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |